Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
20 September 2024
What similarly acting projects are still unpartnered?
24 April 2024
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
24 April 2024
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
24 April 2024
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
24 April 2024
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
23 April 2024
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
22 April 2024
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
Recent Quick take
- 18 August 2023
- 16 August 2023
- 11 August 2023
- 8 August 2023
- 7 August 2023
- 7 August 2023
- 4 August 2023
- 3 August 2023
- 1 August 2023
- 27 July 2023